Vilaiyuk Soamarat, Lerkvaleekul Butsabong, Thammanichanond Duangtawan
Division of Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand.
Histocompatibility & Immunogenetics Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clin Rheumatol. 2022 Jan;41(1):203-212. doi: 10.1007/s10067-021-05875-5. Epub 2021 Aug 6.
Expression of human leukocyte antigen B27 (HLA-B27) has been identified as a predictor of severe disease in enthesitis-related arthritis (ERA) patients. However, the associations between HLA-B27 subtypes and outcomes of this disease are still unclear. Here, we examined the distributions of HLA-B27 subtypes among ERA patients and the associations with disease outcomes.
This was a historical cohort study of ERA patients. Patients were followed from diagnosis to the most recent visit. Relationships between outcomes and the HLA-B27 subtype were assessed by mixed-effect regression, Kaplan-Meier survival, and Cox proportional hazards regression analyses.
Of the 66 ERA patients, 50 HLA-B27-positive (86% male) and 16 HLA-B27-negative (69% male) patients were included in this study. Patients with HLA-B27-positive were classified into HLA-B27:04-positive (84%), including combined HLA-B27:04 and HLA-B27:07 (2%), and HLA-B27:04-negative (16%), including HLA-B27:05 (10%), HLA-B27:06 (2%), HLA-B27:07 (2%), and HLA-B27:15 (2%). HLA-B27:04-positive (83.3%) and HLA-B27:04-negative patients (100%) had refractory disease more than HLA-B27-negative patients (37.5%, p = 0.001). HLA-B27:04-negative patients (57%, 1.73 years) had relapsing disease more and earlier than HLA-B27:04-positive (35%, 5.54 years) and HLA-B27-negative patients (40%, 6.92 years; p < 0.001). Furthermore, HLA-B*27:04-negative was predictors of refractory disease (HR 4.56, 95%CI 1.40-14.87; p = 0.012) and relapsing disease (HR 3.80, 95% CI 1.18-12.30; p = 0.026). The duration before anti-tumor necrosis factor treatment initiation > 1 year was also a predictor of refractory disease (HR 116.08, 95% CI 14.67-918.26; p < 0.001).
HLA-B27:04 was the most common HLA-B27 subtype in Thai ERA patients. HLA-B27:04-negative was associated with more unfavorable outcomes than HLA-B27:04-positive and HLA-B27-negative patients. Key Points • Most ERA patients in Thailand had HLA-B27-positive, and HLA-B27:04 was the most common HLA-B27 allele in these patients. • The outcomes of ERA were associated with the presence of HLA-B27 and its subtypes. • HLA-B27:04-negative patients had unfavorable outcomes, including refractory and relapsing disease, compared to HLA-B27:04-positive and HLA-B27-negative patients.
人类白细胞抗原B27(HLA - B27)的表达已被确定为附着点炎相关关节炎(ERA)患者严重疾病的预测指标。然而,HLA - B27亚型与该疾病结局之间的关联仍不清楚。在此,我们研究了ERA患者中HLA - B27亚型的分布及其与疾病结局的关联。
这是一项针对ERA患者的历史性队列研究。患者从诊断开始随访至最近一次就诊。通过混合效应回归、Kaplan - Meier生存分析和Cox比例风险回归分析评估结局与HLA - B27亚型之间的关系。
本研究纳入了66例ERA患者,其中50例HLA - B27阳性(86%为男性)和16例HLA - B27阴性(69%为男性)。HLA - B27阳性患者被分为HLA - B27:04阳性(84%),包括HLA - B27:04和HLA - B27:07合并型(2%),以及HLA - B27:04阴性(16%),包括HLA - B27:05(10%)、HLA - B27:06(2%)、HLA - B27:07(2%)和HLA - B27:15(2%)。HLA - B27:04阳性患者(83.3%)和HLA - B27:04阴性患者(100%)比HLA - B27阴性患者(37.5%,p = 0.001)有更多难治性疾病。HLA - B27:04阴性患者(57%,1.73年)比HLA - B27:04阳性患者(35%,5.54年)和HLA - B27阴性患者(40%,6.92年)有更多且更早的复发疾病(p < 0.001)。此外,HLA - B*27:04阴性是难治性疾病(HR 4.56,95%CI 1.40 - 14.87;p = 0.012)和复发疾病(HR 3.80,95%CI 1.18 - 12.30;p = 0.026)的预测指标。开始抗肿瘤坏死因子治疗前的持续时间>1年也是难治性疾病的预测指标(HR 116.08,95%CI 14.67 - 918.26;p < 0.001)。
HLA - B27:04是泰国ERA患者中最常见的HLA - B27亚型。与HLA - B27:04阳性和HLA - B27阴性患者相比,HLA - B27:04阴性与更不利的结局相关。要点:•泰国大多数ERA患者HLA - B27阳性,且HLA - B27:04是这些患者中最常见的HLA - B27等位基因。•ERA的结局与HLA - B27及其亚型的存在有关。•与HLA - B27:04阳性和HLA - B27阴性患者相比,HLA - B27:04阴性患者有不利结局,包括难治性和复发性疾病。